Commissariat a L'energie Atomique Et Aux Energies Alternatives

National Institute of Health and Medical Research

Université Joseph Fourier

Thallion Pharmaceuticals Inc.

Centre Hospitalier Universitaire De Grenoble

University Joseph Fourier (Grenoble 1)

Societe Des Systemes Biologiques

Universite Jospeh Fourier

Université Grenoble Alpes

Centre Hospitalier Universitaire Grenoble Alpes

Centre Hospitalier Universitaire Grenoble

François Berger

Jean-Paul Issartel

Adrien Mombrun

Henriette Gourdeau

Mohamed-Ali Bouamrani

Matthieu Dreyfus

Ali Bouamrani

David Ratel

Laurent Pelletier

Sandra Boccard

Patrice Caillat

Chris M Farnet

James B McAlpine

Alim-Louis Benabid

Maxime Ranger

Raymond Campagnolo

Pierre Falardeau

Marie-Line Cosnier

Violetta Dimitriadou

Gary Brandam

Clarence Deffaud

Julien Roux

Affif Zaccaria

Renaud Montessuy

Emmanuel Gay

Jean-Guy Passagia

Bryan Simard

The invention relates to a lateral flow device () for taking at least one analyte of interest in a fluid, comprising:

Lateral flow device comprising sampling

The invention relates to a device () for sampling a biological tissue comprising:

Device for sampling a biological tissue

The invention relates to a device for in vivo sampling of biological species, comprising:&#x2014;a capture medium made from a nanoporous material, having a capture surface for said species, said capture medium being supported by a plate,&#x2014;a gripping rod,&#x2014;an articulation comprising a first limb coupled to the gripping rod and a second limb coupled removably to the plate supporting the capture medium, such that the capture surface can be selectively oriented relative to the gripping rod, so as to adjust the orientation of the capture medium relative to the gripping rod.

Device for in vivo sampling of biological species

The invention relates to a device for transiently contacting at least one unit for capturing biological targets with a body fluid containing them, a method for recovering the captured targets for analysis, and a system for contacting and recovering a capture substrate included in said unit. The invention relates to samples obtained in particular in vivo from body fluids of the human body, e.g. circulating body fluids, said fluids possibly containing, as targets, proteins, oligonucleotides such as RNA or DNA, antibodies, enzymes or cells. A contacting device () according to the invention comprises: &#x2014;a sampling tip () having a contacting end intended to be introduced into a medium containing said fluid, and&#x2014;the or each capturing unit which is bound to said end and which comprises a capture substrate () defining a target capturing surface covered with at least one biocompatible and porous crosslinked polymer layer () designed to retain the or each capture substrate and only to allow biological particles including targets smaller than a limiting size to pass through, in such a way that the or each capture substrate is recoverable after said contacting by dissolution of the or each layer.

Device for transiently contacting at least one unit for capturing biological targets with a fluid containing them, method for recovering the captured targets and system for contacting and recovery

The present disclosure relates to a surgical instrument for sampling molecules in an organ which can be accessed directly or via a surgical portal, including:

Surgical instrument for molecular sampling

The present invention relates to a sampling instrument adapted for taking a sample in situ and in vivo or taking a sample ex vivo of a target tissue or body structure, in a maximum quantity of less than 10g, the instrument comprising an elongated active member () with a distal operative end () having at least one retaining surface () arranged for contacting directly the target tissue or body structure, capturing and retaining molecules of the target tissue or body structure thereto.

Method for determining the molecular composition of a target tissue or another body structure, and its diagnostic applications

The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Sensizitation of cancer cells to therapy using sina targeting genes from the 1P and 19Q chromosomal regions

Sensizitation of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions

This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms by administration of the farnesylated dibenzodiazepinone compound of Formula I via continuous intravenous infusion. The invention includes pharmaceutical compositions comprising the compound of Formula I: 

Methods for administration of a farnesyl dibenzodiazepinone

This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I. The invention includes pharmaceutical compositions comprising the compound of Formula I: 

Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions

Growing community of inventors

Meylan, France

François Berger